RET and medullary thyroid gland carcinoma: Germline-activating RET variants cause multiple endocrine neoplasia type 2 (MEN2), which is a hereditary cancer syndrome associated with medullary thyroid cancer (MTC) in nearly 100% of patients and pheochromocytoma (PCC) in approximately 50% of patients [4].